Last reviewed · How we verify
Brimonidine Tartrate 0.025%
Brimonidine tartrate is an alpha-2 adrenergic agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Brimonidine tartrate is an alpha-2 adrenergic agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Used for Glaucoma or ocular hypertension (Phase 3 development).
At a glance
| Generic name | Brimonidine Tartrate 0.025% |
|---|---|
| Sponsor | Eye Therapies, LLC |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Brimonidine selectively binds to alpha-2 adrenergic receptors on the ciliary body and trabecular meshwork of the eye. This activation reduces aqueous humor synthesis and enhances drainage through the uveoscleral pathway, thereby lowering intraocular pressure. The 0.025% concentration represents a lower-dose formulation designed to minimize systemic absorption and associated side effects.
Approved indications
- Glaucoma or ocular hypertension (Phase 3 development)
Common side effects
- Ocular hyperemia (redness)
- Ocular allergic reactions
- Dry eye
- Follicular conjunctivitis
- Systemic hypotension
Key clinical trials
- Upneeq vs. Lumify Ptosis (PHASE4)
- Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (PHASE4)
- The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients (PHASE4)
- Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution (PHASE3)
- A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness (PHASE3)
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis (PHASE3)
- Brimonidine Eye Drops in the Prevention of Myopia Progression (PHASE2)
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brimonidine Tartrate 0.025% CI brief — competitive landscape report
- Brimonidine Tartrate 0.025% updates RSS · CI watch RSS
- Eye Therapies, LLC portfolio CI